A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers

NCT03258515 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: AZD6094 200 mg
OTHER: Placebo
DRUG: Moxifloxacin

Sponsor

AstraZeneca

Collaborators

[object Object]